DE69931498D1 - Oral zersetzbare tablette mit ausbildung eines zähen schleims - Google Patents

Oral zersetzbare tablette mit ausbildung eines zähen schleims

Info

Publication number
DE69931498D1
DE69931498D1 DE69931498T DE69931498T DE69931498D1 DE 69931498 D1 DE69931498 D1 DE 69931498D1 DE 69931498 T DE69931498 T DE 69931498T DE 69931498 T DE69931498 T DE 69931498T DE 69931498 D1 DE69931498 D1 DE 69931498D1
Authority
DE
Germany
Prior art keywords
tablet
teetile
decomposible
slice
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69931498T
Other languages
English (en)
Other versions
DE69931498T2 (de
Inventor
M Siebert
K Khankari
Unchalee Kositprapa
Indiran Pather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cima Labs Inc
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of DE69931498D1 publication Critical patent/DE69931498D1/de
Application granted granted Critical
Publication of DE69931498T2 publication Critical patent/DE69931498T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
DE69931498T 1998-08-12 1999-08-12 Oral zersetzbare tablette mit ausbildung eines zähen schleims Expired - Lifetime DE69931498T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9626598P 1998-08-12 1998-08-12
US96265P 1998-08-12
US09/372,738 US6368625B1 (en) 1998-08-12 1999-08-11 Orally disintegrable tablet forming a viscous slurry
PCT/US1999/018400 WO2000009090A1 (en) 1998-08-12 1999-08-12 Orally disintegrable tablet forming a viscous slurry
US372738 2003-02-21

Publications (2)

Publication Number Publication Date
DE69931498D1 true DE69931498D1 (de) 2006-06-29
DE69931498T2 DE69931498T2 (de) 2007-03-01

Family

ID=26791503

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931498T Expired - Lifetime DE69931498T2 (de) 1998-08-12 1999-08-12 Oral zersetzbare tablette mit ausbildung eines zähen schleims

Country Status (9)

Country Link
US (1) US6368625B1 (de)
EP (1) EP1104288B1 (de)
JP (1) JP2002522471A (de)
AT (1) ATE326951T1 (de)
AU (1) AU742049B2 (de)
CA (1) CA2339992C (de)
DE (1) DE69931498T2 (de)
ES (1) ES2265188T3 (de)
WO (1) WO2000009090A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US7727552B1 (en) 1997-03-28 2010-06-01 Eisai R&D Management Co., Ltd. Oral pharmaceutical preparations decreased in bitterness by masking
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
CN102716101A (zh) 1999-10-29 2012-10-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ES2327898T3 (es) * 2000-03-01 2009-11-05 EISAI R&D MANAGEMENT CO., LTD. Comprimido de desintegracion rapida que contiene poli(alcohol vinilico).
JP4698000B2 (ja) * 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
US20060099245A1 (en) * 2000-08-01 2006-05-11 Manoj Kumar Hydrodynamically balancing oral drug delivery system with biphasic release
EP2283829A1 (de) 2000-10-30 2011-02-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
GB0203984D0 (en) * 2002-02-20 2002-04-03 Mach Ind Etablissements Comsumable container
SI21221A (sl) * 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
DE10244504A1 (de) * 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
EP1603540A2 (de) * 2003-03-14 2005-12-14 Nirmal Mulye Verfahren zur herstellung von tabletten mit verzögerter freisetzung
DE10311585A1 (de) * 2003-03-14 2004-09-23 Basf Ag Wirkstoffhaltige Adsorbate
US20070092583A1 (en) * 2003-04-30 2007-04-26 Tim Clarot Cold remedy composition comprising zinc salts
EP1620075B1 (de) 2003-05-07 2020-06-24 Samyang Biopharmaceuticals Corporation Hochplastische granulate zur herstellung von schnell schmelzenden tabletten
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20050019397A1 (en) * 2003-07-23 2005-01-27 Jacobs Richard L. Cellulosic fiber containing composition
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US8153161B2 (en) * 2003-12-09 2012-04-10 Dainippon Sumitomo Pharma Co., Ltd. Medicament-containing particle and a solid preparation containing the particle
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US20070036853A1 (en) * 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
CA2549642C (en) 2003-12-31 2012-10-30 Cima Labs Inc. Effervescent oral opiate dosage forms and methods of administering opiates
ATE498395T1 (de) * 2003-12-31 2011-03-15 Cima Labs Inc Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
WO2005074658A2 (en) * 2004-01-30 2005-08-18 Glenmark Pharmaceuticals Inc., Usa Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
US20050170014A1 (en) * 2004-01-30 2005-08-04 Anandi Krishnan Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
EP1715853A4 (de) * 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc Zusammensetzungen zur abgabe von hypnotika im bereich der mundschleimhäute und verwendungsverfahren davon
US20060003003A1 (en) * 2004-06-28 2006-01-05 Bakker Johan A Oral sustained release formulation of tedisamil with gastric retention properties
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) * 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE602006007538D1 (de) * 2005-01-06 2009-08-13 Cima Labs Inc Geschmacksunterdrückungssystem für nicht geweichte arzneimittel
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20060281783A1 (en) * 2005-05-25 2006-12-14 Transoral Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
TW200800142A (en) * 2005-09-09 2008-01-01 Univ Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
WO2014007972A2 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
WO2011109340A1 (en) 2010-03-01 2011-09-09 Nova Southeastern University Epinephrine nanop articles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CN101541348A (zh) * 2005-11-03 2009-09-23 红点生物公司 腙衍生物及其用途
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
US20070293582A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
TW200815048A (en) * 2006-06-05 2008-04-01 Verus Pharmaceuticals Inc Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2008024364A2 (en) * 2006-08-22 2008-02-28 Redpoint Bio Corporation Heterocyclic compounds as sweetener enhancers
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008033545A2 (en) * 2006-09-15 2008-03-20 Redpoint Bio Corporation Triphenylphosphine oxide derivatives and uses thereof
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
WO2008079245A2 (en) * 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
US8193168B2 (en) * 2007-02-02 2012-06-05 Redpoint Bio Corporation Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release
AU2008216867B2 (en) * 2007-02-09 2014-01-30 Durect Corporation Transoral dosage forms comprising sufentanil and naloxone
KR101122469B1 (ko) 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
US20100190739A1 (en) * 2008-12-15 2010-07-29 Fleming And Company, Pharmaceuticals Rapidly Dissolving Vitamin Formulation and Methods of Using the Same
US20100163805A1 (en) * 2008-12-31 2010-07-01 Youngtack Shim Agent-containing media and methods therefor
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20120164083A1 (en) 2009-09-04 2012-06-28 Redpoint Bio Corporation Sweetness Enhancers Including Rebaudioside A or D
MX2012003489A (es) 2009-09-22 2012-07-30 Redpoint Bio Corp Polimorfos novedosos de rebaudiosida c y metodos para elaborarlos y utilizarlos.
CA2782285A1 (en) 2009-12-02 2011-06-09 Luigi Mapelli Fexofenadine microcapsules and compositions containing them
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
EP3118304B1 (de) 2011-08-08 2019-03-13 International Flavors & Fragrances Inc. Zusammensetzungen und verfahren für die biosynthese von vanillin oder vanillin-beta-d-glucosid
EP2753321B1 (de) 2011-10-21 2021-12-15 Nova Southeastern University Epinephrinnanopartikel, herstellungsverfahren dafür und verfahren zur verwendung davon zur behandlung von leiden als reaktion auf epinephrin
WO2014145699A1 (en) * 2013-03-15 2014-09-18 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
EP3888642A1 (de) 2013-03-22 2021-10-06 Nova Southeastern University Feine epinephrinteilchen und verfahren zur verwendung davon zur behandlung von auf epinephrin reagierenden zuständen
EP3068227A4 (de) * 2013-11-11 2017-06-21 Forest Laboratories Holdings Limited Zusammensetzungen und verfahren zur behandlung von fosfomycin-dinatrium
EP2880992A3 (de) 2013-12-05 2015-06-17 International Flavors & Fragrances Inc. Rebaudiosid C und dessen als Stereoisomere als Naturprodukt-Süßkraftverstärker
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011950A (en) 1959-05-19 1961-12-05 Colgate Palmolive Co Liquid composition containing discrete gaseous bodies
US3142621A (en) 1961-11-02 1964-07-28 Ciba Geigy Corp Alginate suspensions of oral pharmaceutical compositions with improved taste qualities
US3456049A (en) 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4414198A (en) 1982-04-23 1983-11-08 Joseph Michaelson Rapidly disintegrable tablet composition and method
US4454110A (en) 1982-05-24 1984-06-12 Forsyth Dental Infirmary For Children Self-gelling liquid composition for topical application in the oral cavity
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8426152D0 (en) 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4687662A (en) * 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5624683A (en) 1986-08-06 1997-04-29 Eisai Co., Ltd. Sustained-release multi-granule tablet
US5288500A (en) 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
US4950689A (en) 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
US5215752A (en) 1988-03-17 1993-06-01 Vectorpharma International S.P.A. Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
US5273823A (en) 1988-10-11 1993-12-28 The Dow Chemical Company Shaped articles containing copolymers of polybenzazoles
US4883660A (en) 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5102664A (en) 1989-07-19 1992-04-07 Day Charles E Good-tasting gritty drug formulations
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
SE9003904D0 (sv) 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
CA2116563C (en) 1991-08-30 2001-07-03 Yoji Ito Dry gel pharmaceutical composition
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5545423A (en) 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5368862A (en) 1991-12-18 1994-11-29 Merck & Co., Inc. Sustained release tablets containing alginate
ATE210968T1 (de) * 1992-02-18 2002-01-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von schnelllöslicher tabletten und schnelllöslichen tablette beinhaltend xylitol
US5422122A (en) 1992-08-04 1995-06-06 Eurand America, Incorporated Controlled release potassium chloride tablet
IL104283A (en) 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
FR2732217B1 (fr) * 1995-03-29 1997-06-06 Hesnard Xavier Forme d'administration solide a usage oral
JP2919771B2 (ja) * 1995-04-17 1999-07-19 佐藤製薬株式会社 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤
US20010014340A1 (en) * 1996-06-14 2001-08-16 Motohiro Ohta Intrabuccally rapidly disintegrating tablet
EP1380308B1 (de) * 1996-07-12 2008-07-09 Daiichi Pharmaceutical Co., Ltd. Schnell zerfallende, druckgeformte Materialien sowie Prozess zu deren Herstellung
FR2753097A1 (fr) * 1996-09-11 1998-03-13 Barrau Francois Gel aqueux ou hydroalcoolique extemporane a viscosite controlee
WO1998014179A1 (en) * 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
JPH10182436A (ja) * 1996-10-31 1998-07-07 Takeda Chem Ind Ltd 固形医薬製剤
JPH10167958A (ja) * 1996-12-09 1998-06-23 Sankyo Co Ltd ロキソプロフェンナトリウム類を含有する口腔内速溶性製剤及びその製造方法
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations

Also Published As

Publication number Publication date
JP2002522471A (ja) 2002-07-23
AU742049B2 (en) 2001-12-13
CA2339992C (en) 2006-01-03
WO2000009090A1 (en) 2000-02-24
DE69931498T2 (de) 2007-03-01
US6368625B1 (en) 2002-04-09
ES2265188T3 (es) 2007-02-01
ATE326951T1 (de) 2006-06-15
EP1104288B1 (de) 2006-05-24
EP1104288A1 (de) 2001-06-06
EP1104288A4 (de) 2003-04-16
CA2339992A1 (en) 2000-02-24
AU5482399A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
DE69931498D1 (de) Oral zersetzbare tablette mit ausbildung eines zähen schleims
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
KR840000228A (ko) 조제성 혼합물에 있어서 건성분말의 제조방법
ATE65023T1 (de) Pharmazeutische mittel.
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
ES2177609T3 (es) Pluma de administracion de medicacion con una escala para fijacion de la dosis.
MY118371A (en) Tetrahydrolipstatin containing compositions
ATE340563T1 (de) DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
NZ507566A (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
ATE138562T1 (de) Transmukosale dosisform
HK1050313A1 (en) Oral transmucosal drug dosage using solid solution
ES2062779T3 (es) Forma de dosificacion para suministrar farmacos al intestino.
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
WO2002067903A3 (en) Compositions and methods of manufacture for oral dissolvable dosage forms
WO2005053658A8 (fr) Capsule molle de butylphthalide et procede de preparation correspondant
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE361122T1 (de) Zahnpflegemittel in portionskapseln
GR20010100377A (el) Φαρμακευτικη συνθεση περιεχουσα σιταλοπραμη
NZ528047A (en) Methods and compositions for masking the taste of pharmaceutically active agents
AU1452402A (en) Novel pharmaceutical formulation in the form of cellulose capsules suitable for benzimidazole derivatives
GB0018322D0 (en) Pharmaceutical compositions
JPS5344617A (en) Drug composition
KR910004181A (ko) 생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태
KR880002537A (ko) 생약제제

Legal Events

Date Code Title Description
8364 No opposition during term of opposition